Clene Files FDA NDA for ALS Drug CNM-Au8 Under Accelerated Approval Pathway
CLNN is trading near its 52-week low of $3.015 (4.8% above the low) on elevated volume (1.9× avg).
Summary
Clene formally submitted its NDA to the FDA for CNM-Au8 in ALS and is asking for accelerated approval, with a confirmatory Phase 3 RESTORE-ALS study in preparation. This is the filing the company flagged in its August 14 8-K, which said it planned to submit in early Q4 2026 — so the timeline held. For a micro-cap trading near its 52-week low, this is the single biggest regulatory step in the story: accelerated approval could put the drug on the market before full confirmatory data lands. The risk is execution and money — the Q2 10-Q carried a going concern warning and a $21.5M net loss, and the company only raised $4M at $3.28 in September, so funding the Phase 3 confirmatory trial is an open question. Next hard checkpoint is FDA acceptance of the filing for review, which would set the review clock and any advisory committee date.
At the time of this announcement, CLNN was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.1M. The 52-week trading range was $3.02 to $13.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.